Resolving Kinase Resistance Landscapes via Antisymmetric Siamese Graph Networks and Co-Folding Ensembles
- 1Department of Chemistry, Indian Institute of Technology Kanpur India, Kalyanpur, Kanpur, Uttar Pradesh, India, 208016
Abstract
Acquired clinical resistance to small-molecule kinase inhibitors arising from single-point mutations within the ATP-binding cleft presents a critical challenge in precision oncology. Conventional computational modeling relies either on rigid docking—which overlooks induced structural alterations—or computationally demanding alchemical free energy perturbation (FEP) methods that cannot scale across wide mutational panels. In this work, we present an end-to-end computational methodology integrating multi-state conformational ensemble generation via the generative biomolecular co-folding engine Boltz with a continuous distance-aware Siamese Graph Neural Network (GNN). Crucially, we introduce an unconstrained bias-free difference head that strictly enforces thermodynamic antisymmetry (f (0) ≡ 0.0 kcal/mol), eliminating trivial baseline drift. Under rigorous 5-fold cross-validation on experimentally characterized kinase resistance pairs, the model achieves an out-of-fold root-mean-square error (RMSE) of 1.637 kcal/mol (MAE = 1.459 kcal/mol, Pearson R = 0.239, Spearman ρ = 0.260). Across a prospective panel of 52 clinical kinase-inhibitor complexes, the architecture structurally rationalizes key resistance patterns, resolving the steric disruption of the ABL1 T315I gatekeeper mutation circumvented by ponatinib and the covalent ablation of EGFR C797S against osimertinib.
Related
- Bayesian neural networks versus deep ensembles for uncertainty quantification in machine learning interatomic potentials
- From Catalytic Networks to Activity Landscapes: A Hierarchical Nonequilibrium Framework for Catalysis
- SPIBER: Reconstructing Free Energy Landscapes from Short, Unconverged Trajectories with Generative Flow Networks
- Site-preference engineering of cobalt active-site ensembles in spinel oxides for oxygen evolution
- Evaluating the Dimensionality of Molecular Ensembles Using Deep Neural Network Stochastic Autoencoders
BibTeX
@misc{naikoo2026resolving,
title = {{Resolving Kinase Resistance Landscapes via Antisymmetric Siamese Graph Networks and Co-Folding Ensembles}},
author = {Sharif Ahmad Naikoo},
howpublished = {ChemRxiv},
year = {2026},
month = oct,
doi = {10.26434/chemrxiv.15009874/v1},
url = {https://chemrxiv.org/doi/full/10.26434/chemrxiv.15009874/v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Resolving Kinase Resistance Landscapes via Antisymmetric Siamese Graph Networks and Co-Folding Ensembles
AU - Sharif Ahmad Naikoo
PY - 2026
DA - 2026/10/05
PB - ChemRxiv
DO - 10.26434/chemrxiv.15009874/v1
UR - https://chemrxiv.org/doi/full/10.26434/chemrxiv.15009874/v1
AB - Acquired clinical resistance to small-molecule kinase inhibitors arising from single-point mutations within the ATP-binding cleft presents a critical challenge in precision oncology. Conventional computational modeling relies either on rigid docking—which overlooks induced structural alterations—or computationally demanding alchemical free energy perturbation (FEP) methods that cannot scale across wide mutational panels. In this work, we present an end-to-end computational methodology integrating multi-state conformational ensemble generation via the generative biomolecular co-folding engine Boltz with a continuous distance-aware Siamese Graph Neural Network (GNN). Crucially, we introduce an unconstrained bias-free difference head that strictly enforces thermodynamic antisymmetry (f (0) ≡ 0.0 kcal/mol), eliminating trivial baseline drift. Under rigorous 5-fold cross-validation on experimentally characterized kinase resistance pairs, the model achieves an out-of-fold root-mean-square error (RMSE) of 1.637 kcal/mol (MAE = 1.459 kcal/mol, Pearson R = 0.239, Spearman ρ = 0.260). Across a prospective panel of 52 clinical kinase-inhibitor complexes, the architecture structurally rationalizes key resistance patterns, resolving the steric disruption of the ABL1 T315I gatekeeper mutation circumvented by ponatinib and the covalent ablation of EGFR C797S against osimertinib.
ER -